混合型肝细胞-胆管癌:细胆管癌是一种独特的分子实体
该研究对18例混合型肝细胞-胆管癌(HCC-CCA)进行基因表达谱、DNA拷贝数检测和外显子组测序,并与独立数据集HCC(n=164)和肝内胆管癌(iCCA)(n=149)比较。整合基因组分析显示细胆管癌(CLC)是与干细胞型和经典型不同的胆管来源实体,干细胞型预后差,经典型HCC与iCCA成分同源。
要点
- 细胆管癌(CLC)为胆管来源的独特实体,表现为NCAM阳性、染色体稳定和TGF-β信号上调。
- 干细胞型HCC-CCA以SALL4阳性、祖细胞样特征和特定致癌通路激活为特点,预后差。
- 经典型HCC-CCA中HCC与iCCA成分拷贝数变异显著相关,提示克隆起源。
核心结论
- 混合型HCC-CCA是异质性肿瘤群体,干细胞型预后差,经典型HCC与iCCA成分同源。
- CLC是独立的胆管来源实体,与染色体稳定性和活跃的TGF-β信号相关。
- 基于新的分子数据,混合型HCC-CCA的病理分类应重新定义。
研究设计与样本
- 对18例混合型HCC-CCA患者的福尔马林固定样本进行基因表达谱、DNA拷贝数检测和外显子组测序,涵盖该病全部组织学谱。
- 使用HCC(n=164)和肝内胆管癌(iCCA)(n=149)的独立数据集进行比较基因组分析。
主要发现
- CLC肿瘤NCAM阳性为6/6 vs 1/12(p<0.001),平均染色体畸变5.7 vs 14.1(p=0.008),TGF-β信号显著上调且炎症相关和免疫应答特征富集(p<0.001)。
- 干细胞型肿瘤SALL4阳性为6/8 vs 0/10(p<0.001),祖细胞样特征富集,MYC和IGF等特定致癌通路激活,并与不良临床结局特征相关。
- 经典型中iCCA与HCC成分的拷贝数变异显著相关,提示克隆起源。
- 外显子组测序显示每肿瘤平均63个非同义突变(平均每个肿瘤2个驱动突变),TP53是HCC-CCA中最常见突变基因(6/21,29%)。
临床怎么用
- 作者认为,基于新的分子数据,混合型HCC-CCA的病理分类应重新定义。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Mixed hepatocellular cholangiocarcinoma (HCC-CCA) is a rare and poorly understood type of primary liver cancer. We aimed to perform a comprehensive molecular characterization of this malignancy. METHODS: Gene expression profiling, DNA copy number detection, and exome sequencing using formalin-fixed samples from 18 patients with mixed HCC-CCA were performed, encompassing the whole histological spectrum of the disease. Comparative genomic analysis was carried out, using independent datasets of HCC (n=164) and intrahepatic cholangiocarcinoma (iCCA) (n=149). RESULTS: Integrative genomic analysis of HCC-CCAs revealed that cholangiolocellular carcinoma (CLC) represents a distinct biliary-derived entity compared with the stem-cell and classical types. CLC tumors were neural cell adhesion molecule (NCAM) positive (6/6 vs. 1/12, p<0.001), chromosomally stable (mean chromosomal aberrations 5.7 vs. 14.1, p=0.008), showed significant upregulation of transforming growth factor (TGF)-β signaling and enrichment of inflammation-related and immune response signatures (p<0.001). Stem-cell tumors were characterized by spalt-like transcription factor 4 (SALL4) positivity (6/8 vs. 0/10, p<0.001), enrichment of progenitor-like signatures, activation of specific oncogenic pathways (i.e., MYC and insulin-like growth factor [IGF]), and signatures related to poor clinical outcome. In the classical type, there was a significant correlation in the copy number variation of the iCCA and HCC components, suggesting a clonal origin. Exome sequencing revealed an average of 63 non-synonymous mutations per tumor (2 mean driver mutations per tumor). Among those, TP53 was the most frequently mutated gene (6/21, 29%) in HCC-CCAs. CONCLUSIONS: Mixed HCC-CCA represents a heterogeneous group of tumors, with the stem-cell type characterized by features of poor prognosis, and the classical type with common lineage for HCC and iCCA components. CLC stands alone as a distinct biliary-derived entity associated with chromosomal stability and active TGF-β signaling. LAY SUMMARY: Molecular analysis of mixed hepatocellular cholangiocarcinoma (HCC-CCA) showed that cholangiolocellular carcinoma (CLC) is distinct and biliary in origin. It has none of the traits of hepatocellular carcinoma (HCC). However, within mixed HCC-CCA, stem-cell type tumors shared an aggressive nature and poor outcome, whereas the classic type showed a common cell lineage for both the HCC and the intrahepatic CCA component. The pathological classification of mixed HCC-CCA should be redefined because of the new molecular data provided.
引用
- Moeini A, Sia D, Zhang Z, et al. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. J Hepatol. 2017. PMID: 28126467. doi:10.1016/j.jhep.2017.01.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。